Meet the expert sessions

Saturday, 1 November 2014 - 08:00- 09:00

 

Short course treatment for MDR-TB 

Measuring the impact of diagnostic testing

WHO guidelines

MDR-TB treatment

Indoor air pollution and tuberculosis

E-cigarettes: existence of evidence?

 

The 'Meet the Expert' sessions bring in experts in various fields, to meet with small groups of participants to discuss, face to face, the challenges and opportunities presented by working to promote lung health.

These sessions are free of charge for registered participants only. The number of persons attending each session should not exceed 30.

Registration for the 'Meet the expert' sessions is available on site, at the conference Registration Desk. Participation will be on a first-come, first-served basis.                                

A1. SHORT COURSE TREATMENT FOR MDR-TB 
Valérie Schwoebel (France), Arnaud Trébucq (France)
Room: 114

 

The current 20-month internationally recommended treatment for MDR-TB is very
disappointing with success rates around 60%, and very expensive. In Bangladesh, Van Deun
et al. have shown that it was possible to cure MDR-TB with almost no relapse and no failure
in 9 months. Following this example, 9 countries in Sub-Saharan Africa are participating in
a study on this registration coordinated by the Union. A lot of other countries all over the
world are willing to test this short-course regimen. Reasons and constraints to implement this
regimen will be discussed.


A2. MEASURING THE IMPACT OF DIAGNOSTIC TESTING
Gavin Churchyard (USA)
Room: 115
 
There are many studies that have evaluated the performance of diagnostic tests but very few that have evaluated patient, programme and population level impact of TB diagnostics. In this session we will review the pipeline of new TB diagnostics, the need for evaluating the impact of new TB diagnostics, and the pros and cons of various approaches to evaluating the impact of new diagnostics.
 
 2. WHO GUIDELINES 
Alberto Matteelli (Switzerland)  
Room: 116
Latent tuberculosis infection (LTBI) affects about one-third of the world's population, of which 10% will develop active TB disease in their lifetime. Systematic testing and treatment of LTBI in at-risk populations is a critical component of WHO’s eight-point framework adapted from the post-2015 Global TB Strategy to target pre-elimination and, ultimately, elimination in low incidence countries. Recognizing the importance of expanding the response to LTBI, in 2014 WHO developed Guidelines on the Management of Latent Tuberculosis Infection. In this session, opportunities and challenges of guidelines implementation will be discussed.

3. MDR-TB TREATMENT

Simon Schaaf (South Africa)
Room: 118/119
 
There is a worldwide increase in awareness of drug-resistant tuberculosis in children. Although the diagnosis remains a challenge, new genotypic diagnostic tests have made confirmation of drug resistance more feasible compared with phenotypic (culture) testing, but the interpretation of these new tests have their own challenges. Treatment with second-line drugs is effective, but the challenge now is optimising dosages and treatment regimens for children  

4. INDOOR AIR POLLUTION AND TUBERCULOSIS

Chen-Yuan Chiang (Taiwan), Hsien-Ho Lin (Taiwan)                                                                                                   Room: 120/121

 

The estimated population attributable fraction of indoor air pollution for tuberculosis (TB) in 22 high TB burden countries was substantial (26.2%), implying that reducing exposure to combustion of solid fuels may have considerable impact in global TB control. However, a recent systemic review and meta-analysis reported that the level of evidence for the association between domestic use of solid fuels and TB was very low. High-quality studies are badly needed to clarify this association and to estimate the magnitude of the problem.

5. E-CIGARETTES: EXISTENCE OF EVIDENCE?

Ehsan Latif (UK), Myra Wisotzky (USA)

Room: 122/123

 

The session will discuss the various challenges posed by e-cigarettes on tobacco control efforts and its relation to the discussions on Non-Communicable Disease control. The experts shall outline the efforts that need to be undertaken to ensure e-cigarettes are properly regulated and their availability monitored both by the governments and civil society.